ADC Therapeutics rises on positive trial data for lymphatic cancer drug combo

ADC Therapeutics SA

12/12/2023 11:31

** Shares of ADC Therapeutics  ADCT.N  rise 17% to $1.17
premarket
    ** Co says a combination of its cancer drug Zynlonta and a
biosimilar of Roche's  ROG.S  Rituxan demonstrated an overall
response rate of 96% in patients with a type of lymphatic cancer
in a mid-stage study 
    ** Zynlonta has already been approved by the U.S. FDA as a
treatment for another type of lymphatic cancer
    ** 4 of 6 brokerages rate the stock "buy" or higher and 2
"hold"; their median PT is $6 - LSEG
    ** Up to Monday's close, stock down 74% YTD

 (Reporting by Puyaan Singh in Bengaluru)
 ((Puyaan.Singh@thomsonreuters.com;))